Skin cancer after nonmyeloablative hematopoietic cell transplantation

M. Cavalier, J. A. Shmalo, M. Yu, S. D. Billings, R. Abonour, Ronelson P. Nelson

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Squamous cell carcinoma (SCC) is the most common skin cancer in patients receiving immunosuppressive therapy, and is well documented to occur in patients that have undergone either solid organ transplantation or conventional myeloablative bone marrow transplantation. Nonmyeloablative hematopoietic cell transplantation (NMAT) provides transient, intensive immunosuppression, permitting allogeneic engraftment without ablating the marrow. The purpose of this report is to describe six patients that developed SCC (n=3), basal cell carcinoma (n=2), or malignant melanoma (n=2) over a period of 2-26 months following NMAT. All patients had myelodysplasia or acute myelogenous leukemia prior to transplantation. The authors demonstrate for the first time that patients who undergo NMAT are at risk for developing skin cancers and emphasize the need for close surveillance in the post transplantation period.

Original languageEnglish (US)
Pages (from-to)1103-1108
Number of pages6
JournalBone Marrow Transplantation
Volume37
Issue number12
DOIs
StatePublished - Jun 1 2006

Fingerprint

Cell Transplantation
Skin Neoplasms
Squamous Cell Carcinoma
Transplantation
Basal Cell Carcinoma
Organ Transplantation
Immunosuppressive Agents
Bone Marrow Transplantation
Acute Myeloid Leukemia
Immunosuppression
Melanoma
Bone Marrow

Keywords

  • Immunosuppression
  • Nonmyeloablative transplantation
  • Skin cancer
  • Squamous cell carcinoma
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Skin cancer after nonmyeloablative hematopoietic cell transplantation. / Cavalier, M.; Shmalo, J. A.; Yu, M.; Billings, S. D.; Abonour, R.; Nelson, Ronelson P.

In: Bone Marrow Transplantation, Vol. 37, No. 12, 01.06.2006, p. 1103-1108.

Research output: Contribution to journalArticle

Cavalier, M. ; Shmalo, J. A. ; Yu, M. ; Billings, S. D. ; Abonour, R. ; Nelson, Ronelson P. / Skin cancer after nonmyeloablative hematopoietic cell transplantation. In: Bone Marrow Transplantation. 2006 ; Vol. 37, No. 12. pp. 1103-1108.
@article{c04066367b7b4fa59b0689333deb4b72,
title = "Skin cancer after nonmyeloablative hematopoietic cell transplantation",
abstract = "Squamous cell carcinoma (SCC) is the most common skin cancer in patients receiving immunosuppressive therapy, and is well documented to occur in patients that have undergone either solid organ transplantation or conventional myeloablative bone marrow transplantation. Nonmyeloablative hematopoietic cell transplantation (NMAT) provides transient, intensive immunosuppression, permitting allogeneic engraftment without ablating the marrow. The purpose of this report is to describe six patients that developed SCC (n=3), basal cell carcinoma (n=2), or malignant melanoma (n=2) over a period of 2-26 months following NMAT. All patients had myelodysplasia or acute myelogenous leukemia prior to transplantation. The authors demonstrate for the first time that patients who undergo NMAT are at risk for developing skin cancers and emphasize the need for close surveillance in the post transplantation period.",
keywords = "Immunosuppression, Nonmyeloablative transplantation, Skin cancer, Squamous cell carcinoma, Stem cell transplantation",
author = "M. Cavalier and Shmalo, {J. A.} and M. Yu and Billings, {S. D.} and R. Abonour and Nelson, {Ronelson P.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1038/sj.bmt.1705362",
language = "English (US)",
volume = "37",
pages = "1103--1108",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Skin cancer after nonmyeloablative hematopoietic cell transplantation

AU - Cavalier, M.

AU - Shmalo, J. A.

AU - Yu, M.

AU - Billings, S. D.

AU - Abonour, R.

AU - Nelson, Ronelson P.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Squamous cell carcinoma (SCC) is the most common skin cancer in patients receiving immunosuppressive therapy, and is well documented to occur in patients that have undergone either solid organ transplantation or conventional myeloablative bone marrow transplantation. Nonmyeloablative hematopoietic cell transplantation (NMAT) provides transient, intensive immunosuppression, permitting allogeneic engraftment without ablating the marrow. The purpose of this report is to describe six patients that developed SCC (n=3), basal cell carcinoma (n=2), or malignant melanoma (n=2) over a period of 2-26 months following NMAT. All patients had myelodysplasia or acute myelogenous leukemia prior to transplantation. The authors demonstrate for the first time that patients who undergo NMAT are at risk for developing skin cancers and emphasize the need for close surveillance in the post transplantation period.

AB - Squamous cell carcinoma (SCC) is the most common skin cancer in patients receiving immunosuppressive therapy, and is well documented to occur in patients that have undergone either solid organ transplantation or conventional myeloablative bone marrow transplantation. Nonmyeloablative hematopoietic cell transplantation (NMAT) provides transient, intensive immunosuppression, permitting allogeneic engraftment without ablating the marrow. The purpose of this report is to describe six patients that developed SCC (n=3), basal cell carcinoma (n=2), or malignant melanoma (n=2) over a period of 2-26 months following NMAT. All patients had myelodysplasia or acute myelogenous leukemia prior to transplantation. The authors demonstrate for the first time that patients who undergo NMAT are at risk for developing skin cancers and emphasize the need for close surveillance in the post transplantation period.

KW - Immunosuppression

KW - Nonmyeloablative transplantation

KW - Skin cancer

KW - Squamous cell carcinoma

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=33745043496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745043496&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705362

DO - 10.1038/sj.bmt.1705362

M3 - Article

C2 - 16757973

AN - SCOPUS:33745043496

VL - 37

SP - 1103

EP - 1108

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -